Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 125-132

  de Boer, Ian H ^a   Astor, Brad C ^b   Kramer, Holly ^c   Palmas, Walter ^d   Seliger, Stephen L ^e   Shlipak, Michael G ^f   Siscovick, David S ^a   Tsai, Michael Y ^g   Kestenbaum, Bryan ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYSTATIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGED; ARTICLE; ASIAN; ATHEROSCLEROSIS; BLOOD; CAUCASIAN; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DISEASE COURSE; ETHNOLOGY; FEMALE; HISPANIC; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEGRO; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; STATISTICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; CYSTATINS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES; LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 38749106643     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03390807     Document Type: Article

References (52)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
2. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145: 237-246, 2006
3. Ritz E, Wanner C: Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol 17[Suppl]: S226-S230, 2006
4. Vaziri ND: Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272, 2006
5. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005
6. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS: Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med 166: 1884-1891, 2006
7. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-17, 2004
8. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140: 167-174, 2004
9. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP: Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47: 312-318, 1995
10. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A: Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36: 29-34, 2000
11. O'Riordan SE, Webb MC, Stowe HJ, Simpson DE, Kandarpa M, Coakley AJ, Newman DJ, Saunders JA, Lamb EJ: Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 40: 648-655, 2003
12. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP: Multi-Ethnic Study of Atherosclerosis: Objectives and design. Am J Epidemiol 156: 871-881, 2002
13. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002
14. Erlandsen EJ, Randers E, Kristensen JH: Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 59: 1-8, 1999
15. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
16. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48: 171-180, 2002
17. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O'Leary DH, Saad MF, Tsai MY, Sharrett AR: LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192: 211-217, 2007
18. Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, D'Agostino RB, Wilson PW, Schaefer EJ: Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham Study. Clin Chem 50: 1189-1200, 2004
19. de Boer IH, Astor BC, Kramer H, Palmas W, Rudser K, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B: Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis August 4, 2007 [epub ahead of print]
20. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
21. Standards of medical care in diabetes-2006. Diabetes Care 29[Suppl 1]: S4-S42, 2006
22. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Bethesda, US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2004
23. Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: A0828, 2001
24. McNutt LA, Wu C, Xue X, Hafner JP: Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 157: 940-943, 2003
25. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. Circulation 95: 69-75, 1997
26. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22: 1175-1180, 2002
27. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI: Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 2: 62-66, 1987
28. Blake GJ, Otvos JD, Rifai N, Ridker PM: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930-1937, 2002
29. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes: A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 46: 674-682, 2003
30. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556-1563, 2006
31. Bjornheden T, Babyi A, Bondjers G, Wiklund O: Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123: 43-56, 1996
32. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ: Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 17: 2507-2514, 1997
33. Tribble DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93: 189-199, 1992
34. Packard CJ, Shepherd J: Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17: 3542-3556, 1997
35. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, de Zeeuw D, de Jong PE: The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 67: 1967-1973, 2005
36. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD: Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 43: 410-418, 1993
37. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C: Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 11: 63-69, 1996
38. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993
39. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P: Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant 9: 1580-1585, 1994
40. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC: Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 13: 2281-2287, 1998
41. Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkila EA: Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301: 1073-1076, 1979
42. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities study. Kidney Int 58: 293-301, 2000
43. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091, 2003
44. Manttari M, Tiula E, Alikoski T, Manninen V: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26: 670-675, 1995
45. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112: 171-178, 2005
46. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613, 2003
47. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269, 2001
48. Madero M, Sarnak MJ, Stevens LA: Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 15: 610-616, 2006
49. Delanaye P, Nellessen E, Cavalier E, Depas G, Grosch S, Defraigne JO, Chapelle JP, Krzesinski JM, Lancellotti P: Is cystatin C useful for the detection and the estimation of low glomerular filtration rate in heart transplant patients? Transplantation 83: 641-644, 2007
50. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS: Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 69: 399-405, 2006
51. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, Barron J, Lemmey A: GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 48: 712-719, 2006
52. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65: 1416-1421, 2004